Roger Perlmutter, Merck
July 30, 2019 08:09 AM EDTUpdated 12:07 PM
Bioregnum
Opinion

Do you want to see what win­ning big in the R&D race looks like in the Big Phar­ma league?

Mer­ck $MRK of­fered a sim­ple les­son in the eco­nom­ics of win­ning a megablock­buster R&D race to­day. And it shouldn’t be missed by any­one.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times